NOD1 receptor is up-regulated in diabetic human and murine myocardium

Clinical Science

Volumn 127, Issue 12, 2014, Pages 665-677

  Prieto, Patricia ^a   Vallejo Cremades, María Teresa ^b   Benito, Gemma ^b   González Peramato, Pilar ^c   Francés, Daniel ^a   Agra, Noelia ^a   Terrón, Verónica ^a   Gónzalez Ramos, Silvia ^a   Delgado, Carmen ^d   Ruiz Gayo, Mariano ^e   Pacheco, Ivette ^f   Velasco Martín, Juan P ^g   Regadera, Javier ^g   Martín Sanz, Paloma ^a   López Collazo, Eduardo ^b   Boscá, Lisardo ^a   Fernández Velasco, María ^b  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d SCHOOL OF MEDICINE   (Spain)

^e UNIVERSIDAD SAN PABLO CEU   (Spain)

^f Hospital Militar   (Nicaragua)

^g UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Apoptosis; Cardiomyocyte; Human myocardium; Inflammation; Nucleotide binding and oligomerization domain 1 (NOD1); Type 2 diabetes

Indexed keywords

CASPASE 3; CASPASE RECRUITMENT DOMAIN PROTEIN 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC CARDIOMYOPATHY; ENZYME ACTIVATION; HEART MUSCLE; HUMAN; HUMAN CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ANIMALS; APOPTOSIS; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DISEASE PROGRESSION; GLUCOSE; HUMANS; MICE; MYOCARDIUM; NF-KAPPA B; NOD1 SIGNALING ADAPTOR PROTEIN; PALMITATES; UP-REGULATION;

EID: 84905900551     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20140180     Document Type: Article

References (56)

1. Haffner, S. M., Lehto, S., Ronnemaa, T., Pyorala, K. and Laakso, M. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229-234
2. Maya, L. and Villarreal, F. J. (2010) Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. J. Mol. Cell Cardiol. 48, 524-529
3. Van Gaal, L. F., Mertens, I. L. and De Block, C. E. (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444, 875-880
4. Komers, R., Lindsley, J. N., Oyama, T. T., Schutzer, W. E., Reed, J. F., Mader, S. L. and Anderson, S. (2001) Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J. Clin. Invest. 107, 889-898
5. Vandanmagsar, B., Youm, Y. H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M. and Dixit, V. D. (2011) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179-188
6. Pickup, J. C., Mattock, M. B., Chusney, G. D. and Burt, D. (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40, 1286-1292
7. Schertzer, J. D., Tamrakar, A. K., Magalhaes, J. G., Pereira, S., Bilan, P. J., Fullerton, M. D., Liu, Z., Steinberg, G. R., Giacca, A., Philpott, D. J. and Klip, A. (2011) NOD1 activators link innate immunity to insulin resistance. Diabetes 60, 2206-2215
8. Wong, F. S., Hu, C., Zhang, L., Du, W., Alexopoulou, L., Flavell, R. A. and Wen, L. (2008) The role of Toll-like receptors 3 and 9 in the development of autoimmune diabetes in NOD mice. Ann. N.Y. Acad. Sci. 1150, 146-148
9. Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H. and Flier, J. S. (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116, 3015-3025
10. Dasu, M. R., Devaraj, S., Park, S. and Jialal, I. (2010) Increased Toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 33, 861-868
11. Meylan, E., Tschopp, J. and Karin, M. (2006) Intracellular pattern recognition receptors in the host response. Nature 442, 39-44
12. Correa, R. G., Khan, P. M., Askari, N., Zhai, D., Gerlic, M., Brown, B., Magnuson, G., Spreafico, R., Albani, S., Sergienko, E. et al. (2011) Discovery and characterization of 2-aminobenzimidazole derivatives as selective NOD1 inhibitors. Chem. Biol. 18, 825-832
13. Harton, J. A., Linhoff, M. W., Zhang, J. and Ting, J. P. (2002) Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains. J. Immunol. 169, 4088-4093
14. Carneiro, L. A., Magalhaes, J. G., Tattoli, I., Philpott, D. J. and Travassos, L. H. (2008) Nod-like proteins in inflammation and disease. J. Pathol. 214, 136-148
15. Davis, B. K., Wen, H. and Ting, J. P. (2011) The inflammasome NLRs in immunity, inflammation, and associated diseases. Ann. Rev. Immunol. 29, 707-735
16. Gatheral, T., Reed, D. M., Moreno, L., Gough, P. J., Votta, B. J., Sehon, C. A., Rickard, D. J., Bertin, J., Lim, E., Nicholson, A. G. and Mitchell, J. A. (2012) A key role for the endothelium in NOD1 mediated vascular inflammation: comparison to TLR4 responses. PLoS One 7, e42386
17. Moreno, L., McMaster, S. K., Gatheral, T., Bailey, L. K., Harrington, L. S., Cartwright, N., Armstrong, P. C., Warner, T. D., Paul-Clark, M. and Mitchell, J. A. (2010) Nucleotide oligomerization domain 1 is a dominant pathway for NOS2 induction in vascular smooth muscle cells: comparison with Toll-like receptor 4 responses in macrophages. Br. J. Pharmacol. 160, 1997-2007
18. Nishio, H., Kanno, S., Onoyama, S., Ikeda, K., Tanaka, T., Kusuhara, K., Fujimoto, Y., Fukase, K., Sueishi, K. and Hara, T. (2011) Nod1 ligands induce site-specific vascular inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 1093-1099
19. Moreno, L. and Gatheral, T. (2013) Therapeutic targeting of NOD1 receptors. Br. J. Pharmacol. 170, 475-485
20. Ture-Ozdemir, F., Tulunay, A., Elbasi, M. O., Tatli, I., Maurer, A. M., Mumcu, G., Direskeneli, H. and Eksioglu-Demiralp, E. (2013) Pro-inflammatory cytokine and caspase-1 responses to pattern recognition receptor activation of neutrophils and dendritic cells in Behcet's disease. Rheumatology 52, 800-805
21. Ver Heul, A. M., Fowler, A., Ramaswamy, S. and Piper, R. C. (2013) Ubiquitin regulates caspase recruitment domain mediated signaling by nucleotide binding oligomerization domain proteins NOD1 and NOD2. J. Biol. Chem. 288, 6890-902
22. Fernandez-Velasco, M., Prieto, P., Terron, V., Benito, G., Flores, J. M., Delgado, C., Zaragoza, C., Lavin, B., Gomez-Parrizas, M., Lopez-Collazo, E. et al. (2012) NOD1 activation induces cardiac dysfunction and modulates cardiac fibrosis and cardiomyocyte apoptosis. PLoS One 7, e45260
23. Inohara, N., Koseki, T., del Peso, L., Hu, Y., Yee, C., Chen, S., Carrio, R., Merino, J., Liu, D., Ni, J. and Nunez, G. (1999) Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J. Biol. Chem. 274, 14560-14567
24. Zhao, L., Hu, P., Zhou, Y., Purohit, J. and Hwang, D. (2011) NOD1 activation induces proinflammatory gene expression and insulin resistance in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 301, E587-E598
25. Shiny, A., Regin, B., Balachandar, V., Gokulakrishnan, K., Mohan, V., Babu, S. and Balasubramanyam, M. (2013) Convergence of innate immunity and insulin resistance as evidenced by increased nucleotide oligomerization domain (NOD) expression and signaling in monocytes from patients with type 2 diabetes. Cytokine 64, 564-570
26. 2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia. Circ. Res. 104, 201-209
27. Zhou, Y. J., Zhou, H., Li, Y. and Song, Y. L. (2012) NOD1 activation induces innate immune responses and insulin resistance in human adipocytes. Diabetes Metab. 38, 538-543
28. Cuda, C., Badawi, A., Karmali, M. and El-Sohemy, A. (2012) Effects of polymorphisms in nucleotide-binding oligomerization domains 1 and 2 on biomarkers of the metabolic syndrome and type II diabetes. Genes Nutr. 7, 427-435
29. Amar, J., Chabo, C., Waget, A., Klopp, P., Vachoux, C., Bermudez-Humaran, L. G., Smirnova, N., Berge, M., Sulpice, T., Lahtinen, S. et al. (2011) Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol. Med. 3, 559-572
30. 2+]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes 55, 608-615
31. Neubauer, N. and Kulkarni, R. N. (2006) Molecular approaches to study control of glucose homeostasis. ILAR J. 47, 199-211
32. Leiter, E. H. and Reifsnyder, P. C. (2004) Differential levels of diabetogenic stress in two new mouse models of obesity and type 2 diabetes. Diabetes. 53 (Suppl. 1), S4-S11
33. Loskutoff, D. J., Fujisawa, K. and Samad, F. (2000) The fat mouse. A powerful genetic model to study hemostatic gene expression in obesity/NIDDM. Ann. N.Y. Acad. Sci. 902, 272-281, discussion 281-272
34. Inohara, N., Ogura, Y., Chen, F. F., Muto, A. and Nunez, G. (2001) Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J. Biol. Chem. 276, 2551-2554
35. Jakopin, Z., Gobec, M., Kodela, J., Hazdovac, T., Mlinaric-Rascan, I. and Sollner Dolenc, M. (2013) Synthesis of conformationally constrained gamma-D-glutamyl-meso-diaminopimelic acid derivatives as ligands of nucleotide-binding oligomerization domain protein 1 (Nod1). Eur. J. Med. Chem. 69, 232-243
36. Masumoto, J., Yang, K., Varambally, S., Hasegawa, M., Tomlins, S. A., Qiu, S., Fujimoto, Y., Kawasaki, A., Foster, S. J., Horie, Y. et al. (2006) Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. J. Exp. Med. 203, 203-213
37. Pickup, J. C. and Crook, M. A. (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41, 1241-1248
38. Xu, X. H., Shah, P. K., Faure, E., Equils, O., Thomas, L., Fishbein, M. C., Luthringer, D., Xu, X. P., Rajavashisth, T. B., Yano, J. et al. (2001) Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104, 3103-3108
39. Edfeldt, K., Swedenborg, J., Hansson, G. K. and Yan, Z. Q. (2002) Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105, 1158-1161
40. Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nunez, G., Schnurr, M. et al. (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361
41. Fritz, J. H., Ferrero, R. L., Philpott, D. J. and Girardin, S. E. (2006) Nod-like proteins in immunity, inflammation and disease. Nat. Immunol. 7, 1250-1257
42. Kanneganti, T. D., Lamkanfi, M. and Nunez, G. (2007) Intracellular NOD-like receptors in host defense and disease. Immunity 27, 549-559
43. Hysi, P., Kabesch, M., Moffatt, M. F., Schedel, M., Carr, D., Zhang, Y., Boardman, B., von Mutius, E., Weiland, S. K., Leupold, W. et al. (2005) NOD1 variation, immunoglobulin E and asthma. Hum. Mol. Genet. 14, 935-941
44. Weidinger, S., Klopp, N., Rummler, L., Wagenpfeil, S., Novak, N., Baurecht, H. J., Groer, W., Darsow, U., Heinrich, J., Gauger, A. et al. (2005) Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J. Allergy Clin. Immunol. 116, 177-184
45. Girardin, S. E., Tournebize, R., Mavris, M., Page, A. L., Li, X., Stark, G. R., Bertin, J., DiStefano, P. S., Yaniv, M., Sansonetti, P. J. and Philpott, D. J. (2001) CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO Rep. 2, 736-742
46. da Silva Correia, J., Miranda, Y., Austin-Brown, N., Hsu, J., Mathison, J., Xiang, R., Zhou, H., Li, Q., Han, J. and Ulevitch, R. J. (2006) Nod1-dependent control of tumor growth. Proc. Natl. Acad. Sci. U.S.A. 103, 1840-1845
47. Cartwright, N., Murch, O., McMaster, S. K., Paul-Clark, M. J., van Heel, D. A., Ryffel, B., Quesniaux, V. F., Evans, T. W., Thiemermann, C. and Mitchell, J. A. (2007) Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. Am. J. Respir. Crit. Care Med. 175, 595-603
48. Zhao, L., Kwon, M. J., Huang, S., Lee, J. Y., Fukase, K., Inohara, N. and Hwang, D. H. (2007) Differential modulation of Nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells. J. Biol. Chem. 282, 11618-11628
49. Hasegawa, M., Fujimoto, Y., Lucas, P. C., Nakano, H., Fukase, K., Nunez, G. and Inohara, N. (2008) A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J. 27, 373-383
50. Magalhaes, J. G., Lee, J., Geddes, K., Rubino, S., Philpott, D. J. and Girardin, S. E. (2011) Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligands. Eur. J. Immunol. 41, 1445-1455
51. Park, J. H., Kim, Y. G., Shaw, M., Kanneganti, T. D., Fujimoto, Y., Fukase, K., Inohara, N. and Nunez, G. (2007) Nod1/RICK and TLR signaling regulate chemokine and antimicrobial innate immune responses in mesothelial cells. J. Immunol. 179, 514-521
52. Nembrini, C., Kisielow, J., Shamshiev, A. T., Tortola, L., Coyle, A. J., Kopf, M. and Marsland, B. J. (2009) The kinase activity of Rip2 determines its stability and consequently Nod1- and Nod2-mediated immune responses. J. Biol. Chem. 284, 19183-19188
53. Barouch, L. A., Gao, D., Chen, L., Miller, K. L., Xu, W., Phan, A. C., Kittleson, M. M., Minhas, K. M., Berkowitz, D. E., Wei, C. and Hare, J. M. (2006) Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ. Res. 98, 119-124
54. da Silva Correia, J., Miranda, Y., Leonard, N., Hsu, J. and Ulevitch, R. J. (2007) Regulation of Nod1-mediated signaling pathways. Cell Death Differ. 14, 830-839
55. Frantz, S., Kobzik, L., Kim, Y. D., Fukazawa, R., Medzhitov, R., Lee, R. T. and Kelly, R. A. (1999) Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J. Clin. Invest. 104, 271-280
56. Larsen, C. M., Faulenbach, M., Vaag, A., Volund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T. and Donath, M. Y. (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526